Loading patent…
AssigneeThe Curators of the University of Missouri
InventorsTimothy J. Hoffman, Wynn A. Volkert, Ning Li, Gary Sieckman, C.A. Higginbotham
Estimating the term…
A compound for use as a therapeutic or diagnostic radiopharmaceutical includes a group capable of complexing a medically useful metal attached to a moiety which is capable of binding to a gastrin releasing peptide receptor. A method for treating a subject having a neoplastic disease includes administering to the subject an effective amount of a radiopharmaceutical having a metal chelated with a chelating group attached to a moiety capable of binding to a gastrin releasing peptide receptor expressed on tumor cells with subsequent internalization inside of the cell. A method of forming a therapeutic or diagnostic compound includes reacting a metal synthon with a chelating group covalently linked with a moiety capable of binding a gastrin releasing peptide receptor.
A compound for use as a therapeutic or diagnostic radiopharmaceutical, said compound comprising a group capable of complexing a metal attached to a moiety capable of binding to a gastrin releasing peptide (GRP) receptor.
A method for treating a subject having a neoplastic disease, said method comprising the steps of.
A method of forming a therapeutic or diagnostic compound comprising the step of reacting a metal complexed with a chelating group with a moiety capable of agonistic binding a gastrin releasing peptide receptor.
A method of forming a therapeutic or diagnostic compound comprising a step of reacting a metal with a chelating group already covalently attached to a moiety capable of agonistic binding a gastrin releasing peptide receptor.
Dependencies are inferred from the claim text.